Published in Biochim Biophys Acta on April 09, 2008
Gold nanoparticles for biology and medicine. Angew Chem Int Ed Engl (2010) 4.14
Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol (2009) 2.99
Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A (2009) 1.94
Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys J (2009) 1.40
Silk-based delivery systems of bioactive molecules. Adv Drug Deliv Rev (2010) 1.37
Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem (2009) 1.36
Antimicrobial peptides with cell-penetrating peptide properties and vice versa. Eur Biophys J (2011) 1.12
Impact of hydrogel nanoparticle size and functionalization on in vivo behavior for lung imaging and therapeutics. Mol Pharm (2009) 1.12
Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol (2010) 1.11
Beauty is skin deep: a surface monolayer perspective on nanoparticle interactions with cells and bio-macromolecules. Small (2011) 1.08
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Cell penetrating elastin-like polypeptides for therapeutic peptide delivery. Adv Drug Deliv Rev (2010) 1.02
Unassisted transport of N-acetyl-L-tryptophanamide through membrane: experiment and simulation of kinetics. J Phys Chem B (2012) 0.98
A novel cell-penetrating peptide derived from human eosinophil cationic protein. PLoS One (2013) 0.97
Enhancing cellular uptake of activable cell-penetrating peptide-doxorubicin conjugate by enzymatic cleavage. Int J Nanomedicine (2012) 0.97
Curb challenges of the "Trojan Horse" approach: smart strategies in achieving effective yet safe cell-penetrating peptide-based drug delivery. Adv Drug Deliv Rev (2013) 0.97
Organelle targeting: third level of drug targeting. Drug Des Devel Ther (2013) 0.97
Engineering building blocks for self-assembling protein nanoparticles. Microb Cell Fact (2010) 0.95
A peptide-based vector for efficient gene transfer in vitro and in vivo. Mol Ther (2011) 0.95
Silk-based gene carriers with cell membrane destabilizing peptides. Biomacromolecules (2010) 0.95
Cell penetrating peptide POD mediates delivery of recombinant proteins to retina, cornea and skin. Vision Res (2009) 0.91
Free energetics of arginine permeation into model DMPC lipid bilayers: coupling of effective counterion concentration and lateral bilayer dimensions. J Phys Chem B (2013) 0.90
Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel) (2012) 0.87
Chondroitin sulfate as a molecular portal that preferentially mediates the apoptotic killing of tumor cells by penetratin-directed mitochondria-disrupting peptides. J Biol Chem (2010) 0.85
A generalizable DNA-catalyzed approach to peptide-nucleic acid conjugation. Chembiochem (2014) 0.84
A common landscape for membrane-active peptides. Protein Sci (2013) 0.83
Molecular interactions between cell penetrating peptide Pep-1 and model cell membranes. J Phys Chem B (2012) 0.83
Peptides used in the delivery of small noncoding RNA. Mol Pharm (2014) 0.83
Non-Viral Delivery and Therapeutic Application of Small Interfering RNAs. Acta Naturae (2013) 0.83
Folic acid-tethered Pep-1 peptide-conjugated liposomal nanocarrier for enhanced intracellular drug delivery to cancer cells: conformational characterization and in vitro cellular uptake evaluation. Int J Nanomedicine (2013) 0.83
Cell-Penetrating Peptides-Mechanisms of Cellular Uptake and Generation of Delivery Systems. Pharmaceuticals (Basel) (2010) 0.81
Hydrophobicity drives the cellular uptake of short cationic peptide ligands. Eur Biophys J (2011) 0.81
Self-assembled lipid nanomedicines for siRNA tumor targeting. J Biomed Nanotechnol (2009) 0.80
Generation of functional insulin-producing cells from mouse embryonic stem cells through 804G cell-derived extracellular matrix and protein transduction of transcription factors. Stem Cells Transl Med (2013) 0.80
CPP-ZFN: a potential DNA-targeting anti-malarial drug. Malar J (2010) 0.79
Glycosylated cell-penetrating peptides and their conjugates to a proapoptotic peptide: preparation by click chemistry and cell viability studies. J Chem Biol (2009) 0.79
Identification of tissue-specific targeting peptide. J Comput Aided Mol Des (2012) 0.78
Augmenting the Efficacy of Immunotoxins and Other Targeted Protein Toxins by Endosomal Escape Enhancers. Toxins (Basel) (2016) 0.78
Tumor targeting of a cell penetrating peptide by fusing with a pH-sensitive histidine-glutamate co-oligopeptide. Biomaterials (2014) 0.78
Antibacterial activities of amphiphilic cyclic cell-penetrating peptides against multidrug-resistant pathogens. Mol Pharm (2014) 0.78
Discovery of a non-cationic cell penetrating peptide derived from membrane-interacting human proteins and its potential as a protein delivery carrier. Sci Rep (2015) 0.78
Nanotechnology for protein delivery: Overview and perspectives. J Control Release (2015) 0.77
Cell-Penetrating Ability of Peptide Hormones: Key Role of Glycosaminoglycans Clustering. Int J Mol Sci (2015) 0.77
Combination of antibody targeting and PTD-mediated intracellular toxin delivery for colorectal cancer therapy. J Control Release (2014) 0.77
Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer. Viruses (2014) 0.77
Assessing histidine tags for recruiting deoxyribozymes to catalyze peptide and protein modification reactions. Org Biomol Chem (2016) 0.76
Cell-penetrating peptides: Possible transduction mechanisms and therapeutic applications. Biomed Rep (2016) 0.76
Endosomal escape efficiency of fusogenic B18 and B55 peptides fused with anti-EGFR single chain Fv as estimated by nuclear translocation. J Biochem (2015) 0.75
Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers. Front Oncol (2013) 0.75
Versatile Two-Step Functionalization of Nanocarbons: Grafting of Propargylic Groups and Click Post-Functionalization. ChemistryOpen (2017) 0.75
Cell Type Preference of a Novel Human Derived Cell-Permeable Peptide dNP2 and TAT in Murine Splenic Immune Cells. PLoS One (2016) 0.75
Identification of cell-penetrating peptides that are bactericidal to Neisseria meningitidis and prevent inflammatory responses upon infection. Antimicrob Agents Chemother (2013) 0.75
The Relation Between Thermodynamic and Structural Properties and Cellular Uptake of Peptides Containing Tryptophan and Arginine. Adv Pharm Bull (2015) 0.75
Drug Delivery Approaches for the Treatment of Cervical Cancer. Pharmaceutics (2016) 0.75
Preparation and optimisation of anionic liposomes for delivery of small peptides and cDNA to human corneal epithelial cells. J Microencapsul (2016) 0.75
Targeting the Tumour: Cell Penetrating Peptides for Molecular Imaging and Radiotherapy. Pharmaceuticals (Basel) (2010) 0.75
Hyperosmotic treatment synergistically boost efficiency of cell-permeable peptides. Oncotarget (2016) 0.75
Design of new acid-activated cell-penetrating peptides for tumor drug delivery. PeerJ (2017) 0.75
Breaking in and busting out: cell-penetrating peptides and the endosomal escape problem. Biomol Concepts (2017) 0.75
CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab (2009) 1.68
UTILLdb, a Pisum sativum in silico forward and reverse genetics tool. Genome Biol (2008) 1.56
Brief intraperitoneal radioimmunotherapy of small peritoneal carcinomatosis using high activities of noninternalizing 125I-labeled monoclonal antibodies. J Nucl Med (2010) 1.45
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res (2007) 1.35
Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy. Clin Cancer Res (2008) 1.30
Differential stage-specific regulation of cyclin-dependent kinases during cambial dormancy in hybrid aspen. Plant J (2004) 1.18
Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother (2010) 1.12
Clinical radioimmunotherapy--the role of radiobiology. Nat Rev Clin Oncol (2011) 1.10
Time-resolved fluorescence resonance energy transfer (TR-FRET) to analyze the disruption of EGFR/HER2 dimers: a new method to evaluate the efficiency of targeted therapy using monoclonal antibodies. J Biol Chem (2011) 1.08
Organellar gene transcription and early seedling development are affected in the rpoT;2 mutant of Arabidopsis. Plant J (2004) 1.02
Mutation detection using ENDO1: application to disease diagnostics in humans and TILLING and Eco-TILLING in plants. BMC Mol Biol (2008) 1.01
Activity-dormancy transition in the cambial meristem involves stage-specific modulation of auxin response in hybrid aspen. Proc Natl Acad Sci U S A (2011) 1.00
Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 1.00
Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers. Proc Natl Acad Sci U S A (2010) 0.99
Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer (2005) 0.98
MHC class I-related chain A conjugated to antitumor antibodies can sensitize tumor cells to specific lysis by natural killer cells. Clin Cancer Res (2005) 0.97
Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia (2013) 0.93
R-Cadherin expression inhibits myogenesis and induces myoblast transformation via Rac1 GTPase. Cancer Res (2008) 0.92
Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen. FEBS J (2009) 0.92
Noninternalizing monoclonal antibodies are suitable candidates for 125I radioimmunotherapy of small-volume peritoneal carcinomatosis. J Nucl Med (2009) 0.91
General overview of radioimmunotherapy of solid tumors. Immunotherapy (2013) 0.89
Single-domain antibody-based and linker-free bispecific antibodies targeting FcγRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther (2013) 0.87
Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb. PLoS One (2013) 0.87
Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach. Eur J Pharm Sci (2009) 0.84
Apoptosis and p53 are not involved in the anti-tumor efficacy of ¹²⁵I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol (2013) 0.84
Quantification of HER expression and dimerization in patients' tumor samples using time-resolved Förster resonance energy transfer. PLoS One (2012) 0.83
The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand. Biochem J (2004) 0.82
Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab')2 after resection of liver metastases from colorectal cancer. Clin Cancer Res (2008) 0.81
Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen. Tumour Biol (2003) 0.80
Fully human IgG and IgM antibodies directed against the carcinoembryonic antigen (CEA) Gold 4 epitope and designed for radioimmunotherapy (RIT) of colorectal cancers. BMC Cancer (2004) 0.80
A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine (2009) 0.80
The human Müllerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4. MAbs (2014) 0.78
Pharmacokinetic and tumor-seeking properties of recombinant and nonrecombinant anti-carcinoembryonic antigen antibody fragments. Int J Cancer (2002) 0.78
High level prokaryotic expression of anti-Müllerian inhibiting substance type II receptor diabody, a new recombinant antibody for in vivo ovarian cancer imaging. J Immunol Methods (2012) 0.77
Redirecting NK cells mediated tumor cell lysis by a new recombinant bifunctional protein. Protein Eng Des Sel (2008) 0.77
Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody. Int J Radiat Oncol Biol Phys (2003) 0.76
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis. Angew Chem Int Ed Engl (2005) 0.76
The lipid-modulating effects of a CD4-specific recombinant antibody correlate with ZAP-70 segregation outside membrane rafts. Immunol Lett (2010) 0.76
Cyclization of peptides through a urea bond: application to the Arg-Gly-Asp tripeptide. Chembiochem (2010) 0.75
Peptides in receptor-mediated radiotherapy: from design to the clinical application in cancers. Front Oncol (2013) 0.75
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials]. Bull Cancer (2003) 0.75
[Combined anti-EGFR and anti-HER2 monoclonal antibodies: preclinical efficacy in the treatment of pancreatic cancer]. Med Sci (Paris) (2007) 0.75
CD4 ligation excludes the Carma1-Bcl10-MALT1 complex from GM1-positive membrane rafts in CD3/CD28 activated T cells. Cell Immunol (2011) 0.75
A one-step synthesis of 2-Alkyl-5-hydroxychromones and 3-Alkoyl-2-alkyl-5-hydroxychromones. Chem Pharm Bull (Tokyo) (2005) 0.75
[Combination of anti-EGFR and anti-HER2 antibodies: hope in pancreatic cancer treatment]. Bull Cancer (2007) 0.75